May 10, 2022 / 05:00PM GMT
Derik De Bruin - BofA Securities, Research Division - MD of Equity Research
Welcome to the 2022 Bank of America Healthcare Conference live from Las Vegas. I'm Derik De Bruin, the Senior Life Sciences and Diagnostics Tools analyst here at Bank of America. Our next company is QIAGEN and with us is Roland Sackers, CFO; and John Gilardi, Head of IR.
Gentlemen, welcome. Thanks for making the trip over from Germany to do this. We appreciate it. So it's -- we started thinking about this as I watch a number of my competitors move on to other things, it's like I've been covering QIAGEN for 21 years. That's -- which is hard to believe when you sort of think about it, 21 years. And it's been an interesting time sort of over that period. And also for QIAGEN, it's sort of been an interesting few years since 2019. You've had -- you've exited some businesses, you changed CEOs, shareholders voted down the Thermo acquisition, but you've improved transparency, you've had COVID pandemic sort of coming through. And it's been a sort of like a real wild roller coaster.
Qiagen NV at Bank of America Healthcare Conference Transcript
Feb 11, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers